Uncommon is focused on RNA therapeutics and has developed advanced nucleic acid delivery technology
Uncommon is focused on RNA therapeutics and has developed advanced nucleic acid delivery technology. They have transitioned from a cultivated meat platform to a new venture with SymphoRNA.
The top three firms on F4's Biotech & Life Sciences investor list.